• Home
  • About Us
  • Contact
  • Subscribe
  • Your Account
  • Login
No Result
View All Result
Tuesday, May 30, 2023
Alternatives Watch
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe
No Result
View All Result
Alternatives Watch
No Result
View All Result

Swiss VC fund allocates to biotech venture incubator

Susan BarretobySusan Barreto
June 9, 2020
in Manager News, Private Equity
Swiss VC fund allocates to biotech venture incubator

Edward Jenner/Pexels

ShareTweetShareSendSend

BB Pureos Bioventures, a newly formed Swiss biotech venture capital fund, announced that it was the first venture capital partner of the Phase II of BaseLaunch — a Basel, Switzerland-based biotech accelerator and incubator.

Pureos joins alongside Roche in supporting the effort with additional partners that will be announced in the coming weeks and months. The venture capital fund invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats.

The fund supports early-stage drug development companies through all stages. Bellevue Asset Management, which manages more than $11 billion and has been active in the healthcare investing since 1993.

Pureos initial portfolio companies include NovaGo Therapeutics, AM Pharma, Eyevensys and Alentis Therapeutics. The Swiss venture capital firm also co-led Alentis’ Series A financing in April 2019. Alentis is known for its treatment of advanced fibrotic diseases, such as liver fibrosis and hepatocellular carcinoma.

“We are delighted to join BaseLaunch, as a partner in the next phase of its company building activities,” said Anja Harmeier, partner at BB Pureos Bioventures. She added that as the sole Swiss venture capital to join, officials at Pureos look forward to developing the partnership further to support and invest in the next generation of innovative drug development companies in Switzerland and beyond.

During 2018 and 2019, BaseLaunch supported nine early therapeutic ventures which have raised a total of more than $100 million in equity capital from U.S. and European venture funds, thereby contributing to the life sciences ecosystem of the Basel Area. Recently, BaseLaunch has added another four ventures to its portfolio, and has been instrumental in contributing to the development of six more ventures in the Basel Area.

During its first phase (2017-2019), BaseLaunch was supported by Roche, Novartis Venture Fund, Johnson & Johnson, Pfizer and Roivant Sciences. The accelerator expects to announce more partners soon.

Tags: BiotechLife SciencesSwitzerland
ShareTweetShareSendSend
Previous Post

Brookfield to invest $260m in energy distribution company

Next Post

Lombard International names new COO

Related Posts

Rhode Island adds to private assets
Consultants

Rhode Island adds to private assets

People moves for week of May 26
Hedge Funds

People moves for week of May 26

Godspeed raises $250m for second investment program
Private Equity

Godspeed raises $250m for second investment program

CPP allocates nearly $6bn to 2023 private equity vintage
Pensions

CPP allocates nearly $6bn to 2023 private equity vintage

New Jersey hires head of private equity
Investor News

New Jersey hires head of private equity

Next Post
Lombard International names new COO

Lombard International names new COO

Log In/Out

Lost your password?

Search the AW Archives

No Result
View All Result

Recent News

BlackRock partners to support infrastructure company

BlackRock partners to support infrastructure company

Callan adds Tony Lissuzzo to Chicago team

Callan adds to Chicago team

April Manager Scorecard: Blockbuster private markets fundraising returns to kick off Q2

April Manager Scorecard: Blockbuster private markets fundraising returns to kick off Q2

Rhode Island adds to private assets

Rhode Island adds to private assets

Be an Alts Insider

Sign up for your FREE daily alts news briefing

Subscribe

Subscribe to AW
Alternatives Watch

© 2019-2022, All Rights Reserved  |  BMV Digital

Navigate Site

  • Investor News
  • Private Equity
  • Private Credit
  • Hedge Funds
  • Real Estate/Infrastructure
  • Subscribe
  • Your Membership
  • Terms of Service
  • Privacy Policy

Follow Us

No Result
View All Result
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe

© 2019-2022, All Rights Reserved  |  BMV Digital

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Be an alts insider

Start your days in the know with our free newsletter

No, I don't want to be an alts insider

Thank

You!

Follow us
on LinkedIn

Lost your password?

This Website Uses Cookies
We use cookies on our website to provide necessary functions. By clicking “Accept”, you consent to the use of all strictly necessary cookies.
Do not sell my personal information.
Cookie Settings Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Save & Accept
Powered by CookieYes Logo